Picking the Dirt, Peeling the Onion:
Interview with Silver Creek's Phillip Butts

By Richard Hefter, Editor, Small Cap Manager

Phillip Butts doesn't mince words about the market. "My outlook over the next 2-3 years is bleak," he says, noting the Dow could sink to as low as 4000. But the 12-15 stocks in his concentrated, small-cap-emphasized portfolio are not market correlated, or so his strategy aims. They're value stocks with catalysts for growth that his risk analysis shows have limited downside. Gauging from the returns of his private accounts, which were up substantially in 2000 and 2001 but gave back some in 2002, his formula is working. Butts, a former Vice President with Donaldson, Lufkin & Jenrette and Senior Vice President with Salomon Smith Barney, shares the strategy behind his three-year-old Santa Barbara-based Silver Creek Equity Management firm, which runs $5-6 million in private equity accounts.

Phillip Butts
Phillip Butts


What's your strategy?

I try to position 12-15 value, special situation, growth stocks for my clients in order to provide another asset class in their overall investment picture. I'm looking for value stocks that have the potential or a catalyst to become growth stocks. Value managers want to buy $1.00 for 50 cents and sell it for 80 cents to $1.00. I'm looking for $1.00 for 50 cents that can end up being a growth stock that will sell at $2.00 or $3.00. Many of these are what I call "onion stocks".

What are onion stocks?

These are stocks where you need to peel off a lot of layers over quarters or even years to realize something that a lot of people want down the road. Those layers can be debt restructurings, lawsuits, asset sales, change in management or new product introductions down the road, etc. I try to position my portfolios and equities so they aren't reliant on the market going up, or the economy getting better, in order to outperform. And that's what we've seen. The last few years with the market down 50 percent, I avoided telecommunication and other overvalued stocks and got into the Mattel's at 10 and the Philip Morris' in the low 20's -- stocks where I didn't think the market made much difference.

You mix larger cap stocks with small caps?

Yes. I'm a big believer in the "dead money" theory, that if investors perceive something to be dead money for years they will sell it no matter how cheap. I don't believe the litigation of Philip Morris -- the worry of bankruptcy -- was as big a factor as the feeling that there were going to be years and years and years of lawsuits and the stock was not going to go anywhere. I understand the tobacco situation very closely, so I was comfortable with the litigation. I was in oil stocks when oil was at $12 a barrel and every oil analyst and every industry analyst was telling us that oil was dead and wasn't going anywhere for many years -- that there was an overcapacity. That's when I say fine, but I'm buying these stocks at or below book value and I'll wait. They're often but not always small caps.

I have a number of stocks at or under cash value, with no debt. I try to stay a little bit lighter on the debt, unless I really know what's going on. I bought Mattel when they had no CEO, when The Learning Company was draining money from them, but I had to have a leap of faith that the board of directors and management were going to make changes. I asked: If it all blows up, what can I sell the assets for? What can I sell Fisher-Price, Hot Wheels and Barbie for in a fire sale? And the numbers I came up with were about $7-$8 a share, so I was happy taking a position at $10 a share. I sold it a year or so later at $21.

Why 12-15 stocks, and how do you manage risk, given your concentrated portfolio?

Everything I've seen in my research shows there's a diminishing marginal return that takes place when you get above 20 stocks. In other words, expanding a portfolio to 50 or 100 stocks does almost nothing for performance. It doesn't minimize downside risk at all. All you're doing is resigning yourself to tracking whatever index of stocks are in your portfolio. It just makes the job easier for money managers to go play golf. I think somebody said if you have two mutual funds in your portfolio you're over-diversified. I'm not saying that 12-15 stocks should be in your entire investment portfolio. I'm saying in the 15 percent of your invested assets that I recommend be in this area, I'm going to have 15 stocks. Which equates to about 1 percent of your entire portfolio per position.

I try to have all my 12-15 stocks non-correlated, so I'm not overexposed to any one industry. I like all of them to be undervalued using a number of valuation methodologies. You really have to go far beyond the P/E, cash flow, EBITDA kind of common valuation methodologies, and I think it takes a lot of time understanding them for each industry and each stock. A lot of valuation is multi-layered and I think the mistakes that are made are sticking to one particular methodology.

What additional methodologies do you use?

Let's look at Tenet Healthcare (THC), for example, here in Santa Barbara, which I had been purchasing in the mid-to-high teens in the late 1990's and sold it at $30 or so. Later, when it was at $50 or $60 the market was really only looking at the P/E. In hindsight they were charging clients too much, pushing earnings numbers higher. If you were looking at another valuation parameter -- the price you're paying in the market cap per hospital bed -- you were paying $1 million per bed. Any rational investor would just run away from something like that. So, that's why I avoided it. It is now in the mid to low teens where the valuations are more reasonable.

On the other hand, for instance, one of my favorite stocks right now is UnitedGlobalCom (UCOMA), which owns almost 70 percent of the largest cable company in Europe, and John Malone and Liberty Media own 75 percent of UnitedGlobalCom. But too much emphasis was placed on current cash flows before the debt restructuring, indicating the stock was overvalued, and not enough emphasis was on what the actual price reflected per user. They were just giving the stock away, and using that valuation metric. I though it was a tremendous buy. UnitedGlobalCom is an example of my ideal investment.

How so?

I want to find a stock where the downside is very small over time if everything goes wrong. UnitedGlobalCom had this big debt restructuring situation in Europe and the stock was down to $1.50 a share, but what the market wasn't looking at was that they had assets -- cable assets -- that they owned in full or in part in Chili, one of the strongest countries in South America, as well as in Argentina, New Zealand and Australia. Any normalized valuation of those properties would give you $1-$1.50 a share.

So, I'm basically buying this company at $1.50 and the downside is almost negligible. Now, Europe could blow up and all those 8 million subscribers and the majority value of this company could go away, and I'd still be left with minimum downside. But if it works, which I felt it would, I'd have a big winner, and it is proving to work. They've gotten through the restructuring, they peeled off the layers of the onion, taken $11 billion in debt and reduced it to $3.5 billion in bank debt. The stock is now at about $4 with a lot of upside over the next several years if growth continues with cable and Internet in Europe. So, in this case, I'm going to be holding it, hoping to get somewhere between a 5 and 10 bagger. This doesn't mean I am only looking for the 10 bagger; generally, I look for 40 to 60 percent moves in my stocks.

How do you find these stocks? Where do you get your ideas from?

I think this is maybe one of the most important aspects of what I bring to the table and what helps manage risk. I think your idea flow and the quality of idea flow is a very important factor in managing risk because a lot of investors stay in fully valued stocks hoping to get a little bit more out of them because they don't have other places to go that are very compelling. So having a lot of good ideas to choose from in any market is key. I have developed over my 16 years in the business a handful of colleagues who I believe share the same valuation methodologies, are very astute, and we share ideas all of the time. This is just one aspect of it. I will get ideas from TV shows, magazines, newsletters I'm involved with. That on top of the investment firms whose research I have access to - Salomon Smith Barney or Bear Stearns, or what have you. The important factor is that I am the final decision maker on all the ideas.

What themes would you say you're playing and what are a couple of stocks that fit into those themes?

As mentioned, I'm buying stocks that are under cash value with little or no debt. Some of these are simply stocks where you just have to be there. I don't have a crystal ball, I don't know if they're going to make it, but I know they're going to have years and years and years of staying power to get through to the next product cycle.

For instance, Palm (PALM) is interesting to me because it's just about at cash value with no debt at $9 a share. I don't know if the next product cycle is going to be in six months or three or four years, but these are the kinds of companies I think can see through to the next cycle. When a cycle hits, multiples kick in and these stocks can be two, three or four times higher, if that happens.

That's why ValueClick (VCLK) is another one of mine I like. With $3 a share in cash and no debt, I was buying it at $2 a share. They're actually making money, and the stock is now at $4.00. They are in Internet advertising. These are things that are going to be with us for a long period of time.

I don't like the computer industry, but was buying SanDisk (SNDK) in the low teens with $5/share in cash net of debt. They make the flashcards for digital cameras and cell phones. That's an area that's just going to keep growing for years and years, and I want to be a part of that.

Sometimes hidden assets compel me to own stocks. When JC Penney (JCP) gets into the low to mid teens I usually buy it. Not for the 1,900 JC Penney stores, but for the 2,900 Eckerd drug stores they own, which in my view are worth as much as the stock at those levels.

As I've said, I always like some cushion down there so if everything goes wrong I've got some asset that's worth a lot of money. I like Metro-Goldwyn-Mayer Inc (MGM) because their film library could be worth more than the current stock price. I'm looking at Midas Muffler (MDS). They're going through a restructuring, got rid of their distribution plants, but the value of their real estate could be worth well above the current stock price. Those kinds of things. But I understand, there has to be some catalyst, something to get the earnings growing, or these are going to be dead for a long period of time.

These are companies I would have thought were large caps but have come down into almost small cap land.

They've been killed. One of my favorite stocks, very controversial, is Vector Tobacco (VGR). They're introducing a nicotine-free cigarette, which has been out for the last couple of months in seven East coast states. They've genetically blocked the production of nicotine in the root. It pays about a 14 percent dividend here, but they are paying the dividend out of capital as income is being used to introduce new products, but the underlying discount cigarette business is what keeps me with this company. Vector is exempt from the MSA payments to the States, so their cash flows are very substantial because of this advantage which helps fund these new products. The first product they had called Omni did not work and it cost them a lot of money, and the stock got hammered from the $30s and low $40s all the way back down to $10-$12. Down here I think the value of the underlying business is worth far more than the current stock price. I also look and see what Gabelli's doing and what Ichan's doing. Ichan owns 20 percent of Vector. There are certain guys out there that I respect, I like their methodologies, so I'll look and follow things they do and may get involved with what they're doing. I'll run the numbers and figure out what the kind of potential upside is if things work out and then marry that with the downside risk and see if that makes sense. With Vector, if Quest is successful, the upside is substantial and the underlying discount business supports the current valuation in my opinion.

What are your thoughts on a more macro level and how does that impact your investing?

I don't disregard the macro level, but it doesn't get in the way of a lot of what I do. Just like I said, in 2000 I thought the market was absurdly overpriced and thought it was at a risk of falling 50 percent, certainly the Nasdaq, yet I was fully invested. Right now, I've been looking for a war rally and I think that could continue. But my outlook over the next two to three years is very bleak. We could muddle through it, but the risk is too great. When you look at other countries, it's easy to see bubbles, it's easy to see Argentina, Mexico in 1995 and Japan 10-12 years ago and say they're out of control. But when you're inside one, it's hard to see the bubble. We're talking about huge consumer, corporate, and government debt levels -- state budget deficit problems. I see a dollar at risk and I see some real problems like interest rates going up perhaps if the dollar falls. I see real estate pulling back and the bottom line is I see consumers who have been spending out of their minds for the last number of years, using their homes as ATM machines, pulling back. That could cause serious problems and I think the Dow could be at risk of going down 40 percent or more from here -- to the 4,000 area. Having said that, it's just going to be a matter of finding more and more opportunities.

11 Micro-Caps Worth Watching

A Message From Our Sponsor:
By John Dutton, President, JM Dutton & Associates, LLC

As one of the largest independent equity research firms in the U.S., Dutton & Associates is helping investors gain high-quality fundamental research on good companies. Many of these companies had little or no research coverage prior to us, and as a result have been under Wall Street's proverbial "radar screen" and trading at prices well below intrinsic value.

Our program of independent research minus any investment banking or brokerage constraints involves a full year of coverage, with an initial report, three quarterly reports, and research notes in between the quarters.

The following are companies we've reported on within the last several weeks, whose reports on our site at www.jmdutton.com may be of interest to you:

First Cash Financial Strong Buy Rating Maintained In Update Report
April 21, 2003. First Cash (FCFS) reported record revenue ($118.8 million) and earnings ($10.9 million) for FY 2002. The 7.6% growth in 2002 revenue resulted from a 4.5% increase in same-store sales (net of jewelry scrap sales) and revenue from 38 new stores opened in 2002. The 39% net income gain is impressive - costs for the new stores were expensed during the year. First Cash maintains a well-planned expansion program, with FY 2003 to add 40 to 50 new stores. Also, improvement in its balance sheet ratios and income statement margins was quite impressive. First Cash projected fully diluted earnings per share of $0.34 to $0.35 for the first quarter of 2003 and reconfirmed its previous 2003 estimate of EPS in a range of $1.28 to $1.31 per FD share. We maintain our 12 month price target of $16.25 based on an expected low-end range of its P/E of 13.5x.

Neurobiological Technologies Buy Rating Maintained In Update Report
April 16, 2003. Clinical data for Neurobiological Technologies' lead product for Alzheimer's disease, Memantine, continues to support a high probability of FDA approval. Results of two separate studies have been recently presented at the American Medical Directors Association annual meeting and at the prestigious American Academy of Neurology Annual Meeting held in Honolulu, Hawaii in early April. NTII's US marketing partner, Forest Laboratories, remains optimistic the FDA will issue an action letter regarding the Memantine submission by the end of 2003. Forest Laboratories' pivotal diabetic neuropathy trial is undergoing data analysis. The last patient was out of follow up in late December and headline study results are expected before the end of April 2003. Paul Freiman, NTII CEO, noted on April 8 that the Company is preparing to begin two Phase III trials during the current quarter for the use of Xerecept in the treatment of peritumoral brain swelling.

Aastrom Biosciences Rating Raised to Strong Speculative Buy
April 10, 2003. Aastrom is experiencing increasing commercial sales of its cell production products. Installations of the Company's AastromReplicell(tm)System for cell replication; the DC-I dendritic cell product for fusion and transfection cell-based therapeutics; the DCV-I antigen-loaded dendritic cell complex; and DCV-II, peptide-loaded dendritic cells at academic research and commercial cancer vaccine development organizations in Europe increased by 20% in the December quarter with its 15 installations of the AastromReplicell System in Europe and the US. On April 1, Aastrom announced the results of a study in which the Company's Tissue Repair Cells were used to safely generate bone in a girl with the genetic bone disease, hypophosphatasia. Our rationale for the rating upgrade is underpinned by the Company's progress, the recent infusion of capital and, in our view, the misguided selling pressure in the Company's shares as a result of investor confusion and concern over the Company's listing status.

CytoGenix Speculative Buy Rating Maintained
April 02, 2003. CytoGenix has added Dr. Cy Stein, a pioneer in the field of the molecular biology of oligonucleotide intervention, to its Board of Directors. CytoGenix continues to add to its base of intellectual property in ssDNA and RNA directed technologies. It develops products that exploit its antisense and DNA enzymatic systems technology, using its proprietary ssDNA expression system to down-regulate proteins associated with viral replication of herpes, shingles or HPV and inflammatory processes such as psoriasis and male pattern baldness. CytoGenix continues to rely on private equity placements to fund operations, and it will be imperative for the Company to raise additional funding in order to pursue its current business plan and operations model. The Company is an unexploited, and still undiscovered company with exciting new technology and carries the inherent risks of a microcap biotechnology company with very limited financial resources. The shares are rated a Speculative Buy.

Buy Rating Issued For Travelzoo
March 27, 2003. Travelzoo Inc. is an on-line publisher of advertisements for travel-providing companies. On its Travelzoo(r) website, www.travelzoo.com, Travelzoo publishes advertisements supplied by its client list of 200 travel-providing companies. This site enjoys high traffic from approximately 4.6 million travel consumers. The Company also publishes the Travelzoo Top 20(tm) e-mail newsletter, top20.travelzoo.com, which is a weekly listing of 20 top money-saving travel deals sent to four million subscribers. We believe the current market valuation of Travelzoo does not reflect its excellent above-average financial history, its experienced management in the Internet advertising market place, nor its potential for revenue growth in the coming years. Future revenue increases will be two-fold as: (1) the database of subscribers increases and (2) the number of advertising clients increases. Revenues were $.9 million in 1999, forecast to be $16.1 million in 2003, while comparable period net income has gone from $.1 million to a forecast $2.6 million in 2003. The Company has no debt.

Nymox Buy Rating Issued
March 26, 2003. Nymox (NYMX) is a young biopharmaceutical company that already has products approved for sale. Its AlzheimAlertTM, a urine test to aid in the diagnosis of early stage Alzheimer's disease, and its NicAlertTM urine and NicoMeterTM saliva tests for monitoring exposure to nicotine, are both first-to-market semi-quantitative tests for their respective marketplaces. These products are in the very early stages of commercial launch. The Company's core technologies, novel neuronal proteins and particle valence medicated immunoassays, allows the Company to develop a range of future products. Its particle valence immunoassay technology can be "ported" to a variety of conditions where point-of-care quantitative tests would be beneficial, such as glucose and cholesterol monitoring. The Company's technology portfolio is sufficiently robust to allow significant partnering or out-licensing opportunities without the risk of "giving away the store." Revenues are forecast to grow to US$2.1 million in 2004 from $0.8 million in 2003. EPS are forecast at $(0.14) for 2002 reducing to $(0.07) in 2004.

LESCO Speculative Buy Rating Issued For Largest Supplier To Professional Lawn Care And Golf Course Market
March 12, 2003. LESCO (LSCO) is the largest supplier to the highly fragmented U.S. professional lawn care and golf course market. It is the industry's largest vertically integrated supplier, offering the most extensive product line, with operations mainly in the Eastern US, primarily in Florida and the Washington, D.C.-Boston corridor. LESCO has substantial opportunity for geographic expansion. A new management team is refocusing LESCO's use of investment capital on expanding and restructuring the Company's historically profitable sales system while divesting less profitable businesses and reining in non-sales overhead costs. Renewed sales momentum should become evident during the spring 2003 season, with sales in 2003, 2004, and 2005 estimated to rise to $547 million, $588 million, and $641million respectively. EPS are estimated at $.72 in 2003, rising to $1.21 in 2005, and to achieve 20% annual growth from 2005 through 2008.

Medicsight Buy Rating Maintained In Update Report
March 10, 2003. With its first Lifesyne(tm) scanning center operational in London, Medicsight's (MSHT) Medicsight(tm) system is now positioned to become a "brand identity" in cost-effective scanning and early disease detection for chronic heart disease and cancer. Lifesyne Centers will scan referred "at-risk" individuals for the highest mortality diseases namely, lung and colorectal cancers, and coronary heart disease. Medicsight's image processing system was reported capable of identifying 100% of isolated pulmonary nodules from CT scans, and uses London's first GE advanced Lightspeed 16-detector multi-slice CT scanner. In its first 30 days of operation, the center performed 130 scans on high-risk patients for coronary heart disease and lung cancer, detecting notable and significant findings in 18% of these patients. Two other Lifesyne centers are expected to open in London during early 2003. In FY2004, Company revenues are estimated at US$14.7 million with EPS of $0.01. The Company has filed for an AMEX listing.

Cap Rock Q4 & 2002 Net Income Soars; EPS For 2002 Hits $6.75
April 15, 2003. Cap Rock Energy (RKE) reported a stronger than expected 4th quarter net income of $1.0 million due to a successful rate increase and the recognition and recovery of previous power costs. They reported 2002 net income of $8.7 million or $6.75 per share. We continue to rate these shares a Strong Buy, with RKE selling at $13.65 representing a P/E of 3.8x our current estimate of 2003 EPS of $3.65 (estimate under review).

Comments on Vita's 2002 Fourth Quarter Results
March 19, 2003. Vita's (VSF) Q4 showed exceptionally strong sales and profitability growth in the new salmon and salad dressing products. Total net sales of $14.7 million were 20% higher than Q4 2001 but gross profit was up by only 7%. SG&A increased by 14% which was a fairly positive result considering (a) the one time auditing fees of $65,000 related to the Halifax transaction and (b) the heavy slotting fees and demo costs totaling $144,000 that were incurred during the introduction of Virginia Brands new salad dressing products to Vita's chain store customers. The notable performance of new products has positive long-term implications, as Vita's internal growth is dependent on the development and introduction of new products. We continue to rate Vita Food as a Strong Buy.

Deckers Outdoor Corporation Reports Strong Operating Performance In 2002 Q4
March 07, 2003. Deckers Outdoor Corporation reported an exceptionally strong operating performance in the Company's 2002 fourth quarter. Teva sales were up by the very impressive rate of 42% to $10.7 million from $7.56 million in the last quarter of 2001. The extension of the Teva line to include closed-toe styles of rugged outdoor footwear is reducing the seasonal imbalance. Nearly all of the $3.14 million increase in Teva sales in the fourth quarter was in the new closed-toe products. The Company anticipates that within three to five years, closed shoes will account for 30% of Teva's sales. Teva sales for the year 2002 were $65.1 million up 6.3% year over year. The closed-toe rugged outdoor sports footwear market is about $2.3 billion compared to $355 million for sport sandals. Considering the Teva acquisition and the sales momentum now apparent in all three product brands, Deckers' stock should attract attention in the coming year. Management's current guidance for 2003 diluted earning per share is a range of $.41 to $.46. We continue to rate the common stock of Deckers Outdoor Corporation as a Buy.

Trinity Biotech Strong Buy Rating Maintained and Target Price Raised
April 07, 2003. The New York Times carried an interesting article on Sunday, April 6, titled "Tech and Health Care Shares Become Silk Purses." It began: "The relatively few stock funds that eked out small gains in a generally money-losing first quarter tended to own health care and technology stocks," and mentioned that winning health care stocks included Amgen (up 19.1%) and Forest Laboratories (up 9.9%). We note that on a relative as well as absolute basis, Trinity Biotech's (TRIB) recent performance has been extraordinary, as it has more than doubled since our basic report of January 27. Since the initial report, our confidence in Trinity's fundamentals has increased incrementally-- due to the better than expected fourth quarter and the apparent success management is having assimilating recent acquisitions. In March, Trinity completed the submission of its PMA to the FDA for its 10-minute test for HIV that is performed on a drop of whole blood, plasma or serum. As discussed previously, this has the potential to become Trinity's single largest product. We have decided it is appropriate to maintain our Strong Buy rating while raising our 12-month target from $2.75 to $3.25.

We invite you to view our full coverage list and read our reports at www.jmdutton.com